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Histamine inhibits formation and release of phagocyte-derived reactive oxygen species, and thereby protects natural killer and T cells
against oxidative damage. Thus, the addition of histamine may potentially improve the efficacy of interleukin-2 (IL-2). Two
randomised phase II trials of IL-2 with or without histamine dihydrochloride (HDC) in patients with metastatic renal cell carcinoma
(mRCC) were run in parallel. A total of 41 patients were included in Manchester, UK and 63 in Aarhus, Denmark. The self-
administered, outpatient regimen included IL-2 as a fixed dose, 18 MIU s.c. once daily, 5 days per week for 3 weeks followed by 2
weeks rest. Histamine dihydrochloride was added twice daily, 1.0mg s.c., concomitantly with IL-2. A maximum of four cycles were
given. The Danish study showed a statistically significant 1-year survival benefit (76 vs 47%, P¼0.03), a trend towards benefit in both
median survival (18.3 vs 11.4 months, P¼0.07), time to PD (4.5 vs 2.2 months, P¼0.13) and clinical benefit (CRþPRþSD) (58 vs
37%, P¼0.10) in favour of IL-2/HDC, whereas the UK study was negative for all end points. Only three patients had grade 4 toxicity;
however, two were fatal. A randomised phase III trial is warranted to clarify the potential role of adding histamine to IL-2 in mRCC.
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Patients with untreated metastatic renal cell carcinoma (mRCC)
have a poor prognosis with a median survival of about 8 months
(Haas et al, 1993), and only 10% survive beyond 3 years (Elson et al,
1988). The results remain poor because mRCC is highly refractory
to therapy, including radiation, hormones and chemotherapy
(Motzer and Russo, 2000). However, immunological manipulation
using interleukin-2 (IL-2) mediate durable tumour regression in 5–
10% of patients lasting 5 and 10 years, and this subgroup of patients
are probably cured (Bordin et al, 2000; Fisher et al, 2000; Negrier
et al, 2000; Atzpodien et al, 2002). Despite this important
improvement, the vast majority of patients will die of their disease
and therefore novel treatment strategies or identification of new
agents with better antitumour activity remain a high priority.
The explanation for the low level of treatment success following
IL-2 based immunotherapy is probably extremely complex.
However, the new paradigm of tumours arising and persisting in
the setting of chronic inflammation (Pollard, 2004; Vakkila and
Lotze, 2004) may represent one of several factors of importance for
treatment failure. Among macrophage and neutrophil products,
reactive oxygen species (ROS) may not only induce genomic
instability (O’Byrne and Dalgleish, 2001) but also damage
antitumour immune effector cells, especially natural killer (NK)
and T cells (Seaman et al, 1982; Hellstrand et al, 1994a; Hansson
et al, 1996a). Intratumoural macrophages isolated from melanoma
metastases inhibit NK cell function by the release of ROS (Kono
et al, 1996). Intratumoral NK and T cells isolated from mRCC show
sign of oxidative damage (Finke et al, 1993; Tartour et al, 1995).
Interleukin-2 cannot activate NK cells in vitro in the presence of
monocytes or macrophages (Hellstrand and Hermodsson, 1990).
However, histamine dihydrochloride (HDC), acting via H2-type
receptors on phagocytes, has been shown to inhibit the ROS-
production by phagocytes, and therefore protects NK and T cells
from inhibition and apoptosis. Reversal of this oxidative suppres-
sion of NK and T cells may, thus, be important to enhance the
immune response with IL-2 (Hellstrand et al, 2000; Hellstrand,
2002). We have explored this potential mechanism clinically in the
present two randomised phase II trials of IL-2 with or without
HDC in mRCC.
PATIENTS AND METHODS
Aims and objectives
Two parallel randomised, prospective, open-label, phase II trials
were conducted, one in Manchester, UK and one in Aarhus,
Denmark to compare IL-2/HDC vs IL-2-alone as first-line
treatment for mRCC. The two studies had a similar study design
and patient selection criteria. Primary objectives were response
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sand toxicity. Secondary objectives were time to disease progres-
sion, overall survival and 1-year survival.
Patients
The trials were approved by the local ethics committees and the
National Medical Agencies. All subjects gave written informed
consent before inclusion. Main inclusion criteria were inoperable,
bidimensionally measurable, histologically confirmed mRCC,
18–75 years of age, Karnofsky performance status X70, life
expectancy 43 months; haemoglobin 410.0gdl
 1; white blood
cell count 43.0 10
9cellsl
 1; platelet count 4100 10
9l
 1;
partial thromboplastin time and creatinine o1.5 times the upper
limit of normal; serum bilirubin o1.25 the upper limit of normal.
Main exclusion criteria were brain metastasis, central nervous
system disorders, psychiatric disability, pheochromocytoma,
glaucoma, abnormal cardiac function, asthma or systemic allergic
reaction treated within the last 5 years, bleeding ulcer disease,
infections requiring antibiotics, prior chemotherapy, immuno-
therapy or extensive radiotherapy in the last 4 weeks and ongoing
active malignancies except in situ carcinoma of the cervix or
localised carcinomas of the skin.
Beta-blocker medications, H2 receptor antagonists and steroidal
medications were not allowed. H1 receptor antagonists were
allowed o5 days to treat skin itching.
Treatment
Patients were consecutively randomised by center to receive either
IL-2/HDC or IL-2 alone. One cycle consisted of IL-2 (Aldesleukin,
rIL-2, Proleukin
s, Chiron, The Netherlands) as a fixed dose, 18
MIU s.c. once daily, 5 days per week for 3 weeks followed by 2
weeks rest. HDC (Ceplenet, supplied by Maxim Pharmaceuticals
Inc, San Diego, USA) 1.0mg, was added twice daily by a slow 20-
min injection s.c., concomitantly with IL-2. Patients were evaluated
for objective response every two cycles. A maximum of four
treatment cycles was given.
Due to the outpatient nature of this protocol, patients received
instruction, guidance and monitoring during the first days of IL-2
and histamine injections before self-administration at home. Only
a few subjects required home care nursing for the injections.
Evaluation of patients
Toxicity evaluation, physical examination and laboratory tests
were performed every 5 weeks. Patients were evaluated for
response after two and four cycles, if appropriate, and thereafter
every third month until progressive disease (PD) was observed.
Responses were reconfirmed after at least 4 weeks.
Objective response was defined according to the standard
WHO criteria (Miller et al, 1981): (a) complete response (CR),
defined as total disappearance of all clinical disease; (b) partial
response (PR), defined as a reduction of more than 50% in the
bidimensionally product diameter; (c) stable disease (SD), defined
as a reduction of less than 50% or an increase in size of less
than 25%; and (d) PD, defined as an increase in size of more than
25% in the bidimensionally product diameter or appearance of
new lesions.
Dose modifications
Toxicity was graded according to NCI common toxicity criteria,
version 2.0. In general, no dose reduction of either study drug was
done in case of grade 1 or 2 toxicity. In case of grade 3 or 4 toxicity,
treatment was interrupted until toxicity returned to grade 1 or less
or grade 2 or less. In most cases, IL-2 was then restarted at the 50%
dose level and histamine at the 100% dose level.
Management of toxicity
All patients received the following as needed to minimise toxicity:
paracetamol, metoclopramide, ondansetron, loperamide, omepra-
zole, furosemide or mucopolysaccharidepolysulphate.
Follow-up
Responses were evaluated every 3 months until PD. Patients were
followed for survival every 3 months until death. No patients
were lost to follow-up.
Statistical methods
Treatment differences in response rates and other proportions
were compared using Fisher’s exact test. Time to PD was measured
from first day of treatment until disease progression. Overall
survival was measured from first day of treatment until death
or last follow-up evaluation. The cumulated survival rate was
estimated by the Kaplan–Meier method. The log-rank test was
used to analyse survival differences among subgroups of patients.
All calculations were performed using SPSS 11.0 statistical
software. The survival data were updated 14 April 2005.
RESULTS
Between June 1999 and August 2001, 41 patients were enrolled
at the Department of Medical Oncology, Christie Hospital,
Manchester, UK. Between August 2000 and August 2002, 63
patients were enrolled at the Department of Oncology, Aarhus,
Denmark. The median follow-up time was 55 and 43 months,
respectively, and the minimum length of follow-up 49 and 32
months, respectively. Separate analyses were carried out for the
two studies as the trials were run independently. All patients met
the eligibility criteria and were evaluable for toxicity. Number of
patients receiving the planned drug dose was not significantly
different between treatment arms in either of the two centres. Two
patients in Manchester and four patients in Aarhus were
nonevaluable for response as they stopped treatment within the
first treatment cycle due to toxicity without signs of PD.
Table 1 lists baseline patient characteristics for the two patient
populations. Patient characteristics were generally well balanced
across treatment arms in the two studies, although slightly more
Danish patients on the IL-2 arm had liver metastases (P¼0.17)
and slightly more Danish patients on the IL-2/HDC arm were
males (P¼0.10) (Table 1). When comparing the two study centres,
it was noted that the UK patients more often had lung metastasis
only (13/41 vs 2/63) than the Danish patients. More Danish
patients had their primary kidney tumour in situ (26/63 vs 7/41),
had higher frequency of lymph node metastases (38/63 vs 14/41),
bone metastases (22/63 vs 4/41) and number of disease sites (three
or more) (41/63 vs 10/41) than the UK patients.
Tumour response
Based on an intention-to-treat analysis, overall response rates were
not statistically significantly different between treatment groups
(Table 2). However, for the Danish patients, a higher percentage
of clinical benefit (CRþPRþSD) was noted in the IL-2/HDC
group compared with the IL-2-alone group (58 vs 37%, respec-
tively). This difference was of borderline significance (P¼0.10).
Response rates were identical in the two treatment groups in the
UK study (Table 2).
Survival
Kaplan–Meier survival distribution curves for the Danish patients
(n¼63) demonstrated a trend for improved survival for the IL-2
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splus HDC group compared with the IL-2-alone group (Figure 1).
Thus, median survival was improved from 11.4 months (IL-2)
to 18.3 months (IL-2/HDC). This difference was of borderline
significance (log rank P¼0.07) (hazard ratio 0.61, 95% CI: 0.36–
1.05) (Figure 1). The 1-year survival rate was statistically
significantly improved from 47% for the IL-2-alone group to
76% for the IL-2 plus HDC group (P¼0.03). However, Kaplan–
Meier survival curves for the UK patients (n¼41) were almost
identical with no differences in median survival (IL-2, 12.9 months;
IL-2/HDC, 13.2 months, P¼0.6) or in the 1-year survival rate
(IL-2, 55%; IL-2/HDC, 52%) (Figure 1).
At the time of analysis, 36 and 53 patients in the UK and the
Danish study, respectively, had died. Thus, the event rate was 88
and 84%, respectively.
Table 1 Baseline patient characteristics
Aarhus, Denmark Manchester, United Kingdom
IL-2/HDC (N¼33) n IL-2 (N¼30) n IL-2/HDC (N¼21) n IL-2 (N¼20) n
Patients evaluable for response 30 29 20 19
Median age, years (range) 56 (31–69) 60 (36–69) 57 (37–70) 53 (28–71)
Male 26 17 16 18
Karnofsky performance status
100 19 12 3 4
90 10 13 11 12
8 0 2263
7 0 2311
Metastasis-free interval p1 year 23 21 18 14
Prior therapy
Nephrectomy 19 19 16 18
Embolisation — — 2 —
Excision of metastatic lesions 4 2 1 2
Radiotherapy 2 1 2 —
Thalidomide/hormones — 1 — 1
Immunotherapy — — — 3
Number of disease organ sites
13 3 8 7
28 8 6 1 0
3 or more 22 19 7 3
Most common sites of disease
Primary kidney tumour 14 12 5 2
Local recurrence kidney bed 4 6 5 4
Lung/pleura 26 23 17 16
Lung only 2 0 7 6
Lymph node 21 17 7 7
Liver 3 7 2 2
Bone 10 12 3 1
MSKCC prognostic criteria
a
Favourable prognosis 8 5 4 7
Intermediate prognosis 21 19 11 7
Poor prognosis 4 6 1 1
Missing values — — 5 5
aMemorial Sloan-Kettering Cancer Center. J Clin Oncol 1999; 17: 2530–2540.
Table 2 Response to treatment
Aarhus, Denmark Manchester, United Kingdom
IL-2/HDC (N¼33) IL-2 (N¼30) IL-2/HDC (N¼21) IL-2 (N¼20)
n (%) n (%) Pn (%) n (%) P
Evaluable for response 30 29 20 19
C R 21 00
P R 20 33
SD 15 10 9 8
PD 11 18 8 8
Overall response (ITT) 4 (12) 1 (3) 0.36 3 (14) 3 (15) 1.0
Clinical benefit (ITT) 19 (58) 11 (37) 0.10 12 (57) 11 (55) 1.0
CR¼complete response; PR¼partial response; SD¼stable disease; PD¼progressive disease; clinical benefit¼CR+PR+SD; ITT¼intention-to-treat analysis.
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Time to PD was not statistically significantly different for the two
treatment groups in either of the two studies (Figure 2). In the
Danish study, median time to PD was 2.2 months in the IL-2-alone
group and median 4.5 months in the IL-2 plus HDC group (P¼0.13),
whereas time to PD was identical in the two treatment groups in the
UK study (Figure 2). At the time of analysis, only one patient had not
progressed, giving a censoring rate of 1% in total for the two studies.
Toxicity
At least 70% of patients received two cycles of treatment and at
least 23% of patients received four cycles of treatment in the
two studies. A total of 4500 histamine injections were given as self-
administration at home without medical supervision. In general,
toxic effects were minor to moderate. All patients had at least one
toxic side effect. Table 3 lists grade 3/4 toxicity to treatment. There
was generally more reported toxicity among the Danish patients
compared with the UK patients. Concerning nausea and vomiting,
the toxicity was more pronounced in the UK study. However,
toxicity was not significantly different for IL-2-alone compared
with IL-2 plus HDC in either of the studies. In total, only three of
the 104 patients had grade 4 toxicity (lethargy, Escherichia coli
sepsis and thrombocytopenia/bowel infarction, respectively).
These three patients received IL-2/HDC and two of the episodes
were fatal. One patient died due to septicaemia, which was
considered unrelated to the study drug medication. The other
patient died due to thrombocytopenia/bowel infarction and this
death was possibly related to treatment.
DISCUSSION
Since its introduction to the clinic in 1985, IL-2 remains the only
established cytokine approved by the US Food and Drug
Administration for the treatment of mRCC. Despite 20 years of
investigations, no combination therapy has proved better than IL-2
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Figure 1 Kaplan–Meier estimates for overall survival of IL-2 plus
histamine (—) vs IL-2 alone (---). Tick marks represent last date of follow-
up. (A) Aarhus, n¼63, (B) Manchester, n¼41.
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Figure 2 Kaplan–Meier estimates for progression-free survival of IL-2
plus histamine (—) vs IL-2 alone (---). (A) Aarhus, n¼63, (B) Manchester,
n¼41.
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McDermott et al, 2005).
Histamine dihydrochloride as an adjunct to IL-2 is an example
of translational research from basic biology to clinical trials.
A large number of in vitro and in vivo observations from
independent laboratories have supported the observation of
oxidative suppression of NK and T cells by phagocytes (i.e.
monocytes, macrophages and neutrophils) (Seaman et al, 1982;
Finke et al, 1993; Tartour et al, 1995; Hansson et al, 1996a; Kono
et al, 1996; Saio et al, 2001). Hellstrand and co-workers have
demonstrated that histamine protects NK and T cells against
oxygen radical-induced dysfunction and apoptosis by specifically
blocking the formation and release of hydrogen peroxide (H2O2)
from phagocytes, and moreover, maintains the activation of NK
and T cells by IL-2 (Hellstrand and Hermodsson, 1986, 1990, 1991;
Hellstrand et al, 1990, 1994a,b; Asea et al, 1996; Hansson et al,
1996b, 1999). This potential mechanism has been explored
clinically in acute myelogenous leukaemia (Brune and Hellstrand,
1996), chronic hepatitis C (Lurie et al, 2002), multiple myeloma
(Mellqvist et al, 1999), metastatic melanoma (Agarwala et al, 2002,
2004; Schmidt et al, 2002) and mRCC (Donskov et al, 2002).
We introduced histamine in mRCC in combination with low-
dose IL-2 and IFN-a (Donskov et al, 2002). In parallel with the
clinical trial, we obtained serial blood samples and tumour
biopsies, searching for a potential histamine effect in situ
(Donskov et al, 2004). However, in that low-dose schedule of
IL-2 and IFN-a, histamine did not appear to add efficacy with
respect to response (Donskov et al, 2002). Moreover, no
discernable differences in the examined immunologic parameters
in blood and tumour tissue could be detected between histamine-
and nonhistamine-treated patients (Donskov et al, 2004).
However, the question of whether histamine might improve
efficacy with higher doses of IL-2 formed the basis for the present
studies representing the first randomised trials in mRCC evaluat-
ing the efficacy and safety of subcutaneous IL-2 in combination
with HDC. Thus, in the present study, we have doubled the dose of
IL-2 compared to that in our first IL-2/IFN/histamine-study and
the applied IL-2 dose can be considered to be an intermediate dose
level. Protocol criteria were similar in the two studies. However,
the Danish patients had a significantly greater disease burden than
UK patients. The outcome of the individual studies differed as the
Danish study showed a statistically significant 1-year survival
benefit and a trend towards benefit in both overall survival and
clinical benefit (CRþPRþSD) in favour of IL-2/HDC, whereas
the UK study was negative for all end points. This means that the
potential effect of histamine was only indicated in the Danish study
and by that in the group of patients with the worse prognosis. The
explanation for this difference in the outcome of the two trials is
unclear, but it should be emphasised that the different outcome
may have been obtained by pure chance.
In the Danish patients, we also assessed the oxidative stress
hypothesis by monitoring cells of potential benefit (i.e. NK and
T cells) and cells of potential harm (i.e. monocytes/macrophages
and neutrophils) simultaneously in blood and tumour tissue,
before and during treatment. These assays provide compelling
evidence for circulating monocytes and neutrophils as powerful
negative prognostic factors for IL-2 based immunotherapy and
establish a biological rationale for the addition of histamine to IL-2
in mRCC. Thus, targeting H2O2 by histamine seems to enhance the
antitumour activity of IL-2 in situ in a subgroup of patients with
low monocytes/neutrophils or high NK cells. These results will be
published separately.
Toxicity was in general manageable in an outpatient setting,
although we observed one possible toxic death. Adverse events
noted in patients treated with the combination of IL-2 and
histamine were almost similar in type and frequency as toxicities
in patients treated with IL-2 alone.
In conclusion, the outcome of the individual studies differed as
the Danish study showed a trend towards benefit in favour of
IL-2/HDC, whereas the UK study was negative for all end points.
A randomised phase III trial is warranted to clarify the potential
role of adding histamine to IL-2 in mRCC.
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